MakWYLeongCTOngLM, et al.Clinical effectiveness of a Malaysian-manufactured CAPD product: a randomised trial. Peritoenal Dialysis International2021: in press.
2.
MakWYOngLMGohBL, et al.Protocol for a randomised, open-label, parallel group, multicentre controlled study to evaluate the clinical performance and safety of Stay Safe Link compared with Stay Safe in patients with end-stage kidney disease on continuous ambulatory peritoneal dialysis. BMJ Open2019; 9: e024589.
3.
European Chemical Agency. Committee for Risk Assessment (RAC), and Committee for Socio-economic Analysis (SEAC). Opinion on an Annex XV dossier proposing restrictions on four phthalates (DEHP, BBP, DBP, DIBP) ECHA/RAC/RES-O-0000001412-86-140/F, https://echa.europa.eu/documents/10162/4080643e-4b56-c073-f902-bdc936034826(2017, accessed 8 February 2021).
4.
European Chemical Agency. Committee for Risk Assessment (RAC), and Committee for Socio-economic Analysis (SEAC). Background document to the Opinion on the Annex XV dossier proposing restrictions on four phthalates (DEHP, BBP, DBP, DIBP) RES-O-0000001412-86-140/F ECHA/SEAC, https://echa.europa.eu/documents/10162/e603ff27-25ae-2c6d-8210-a65e49046e19(2017, accessed 8 February 2021).
5.
KostićIAnđelkovićTAnđelkovićD, et al.Quantification of DEHP into PVC components of intravenous infusion containers and peritoneal dialysis set before and after UV-A treatment. Bulg Chem Comm2017; 49: 360–365.
6.
MettangTThomasSKieferT, et al.The fate of leached di(2-ethylhexyl)phthalate in patients undergoing CAPD treatment. Perit Dial Int1996; 16: 58–62.
7.
SilanoVBarat BavieraJMBolognesiC, et al.Update of the risk assessment of di-butylphthalate (DBP), butyl-benzyl-phthalate (BBP), bis(2-ethylhexyl)phthalate (DEHP), di-isononylphthalate (DINP) and di-isodecylphthalate (DIDP) for use in food contact materials. Efsa j2019; 17: e05838.
8.
SugimuraKNaganumaTKakiyaY, et al.Endocrine-disrupting chemicals in CAPD dialysate and effluent. Blood Purif2001; 19: 21–23.
9.
McGinnisPMartinezJGadagbuiB, et al.Exposure assessment: potential for the presence of phthalates in selected plastics. Cincinnati, OH: Toxicology Excellence for Risk Assessment (TERA), University of Cincinnati, 2015.
10.
TestaiEHartemannPRastogiSC, et al.The safety of medical devices containing DEHP plasticized PVC or other plasticizers on neonates and other groups possibly at risk (2015 update). Regul Toxicol Pharmacol2016; 76: 209–210.
11.
Center for Devices and Radiological Health, U.S. Food and Drug Administration. Assessment of Di(2-ethylhexyl)phthalate (DEHP) released from PVC medical devices, https://www.fda.gov/media/114001/download(2001, accessed 10 January 2021).
Health Canada (2002). DEHP in medical devices: an exposure and toxicity assessment. Medical Devices Bureau Therapeutic Products Directorate, Health Products & Foods Branch, Health Canada. Revised: February 2002. Irwin Hinberg, PhD, Head, Criteria & Assessment, Research & Surveillance Division, Medical Devices Bureau, Therapeutic Products Directorate.
PanGHanaokaTYoshimuraM, et al.Decreased serum free testosterone in workers exposed to high levels of di-n-butyl phthalate (DBP) and di-2-ethylhexyl phthalate (DEHP): a cross-sectional study in China. Environ Health Perspect2006; 114: 1643–1648.
16.
BarrettJR. Health on the factory floor: occupational phthalate exposure reduces testosterone. Environ Health Perspect2006; 114: A660–A660.
17.
KochHMBoltHMAngererJ. Di(2-ethylhexyl)phthalate (DEHP) metabolites in human urine and serum after a single oral dose of deuterium-labelled DEHP. Archiv Toxicol2004; 78: 123–130.
18.
KochHMBoltHMPreussR, et al.New metabolites of di(2-ethylhexyl)phthalate (DEHP) in human urine and serum after single oral doses of deuterium-labelled DEHP. Archiv Toxicol2005; 79: 367–376.
19.
KochHMPreussRAngererJ. Di(2-ethylhexyl)phthalate (DEHP): human metabolism and internal exposure – an update and latest results1. Int J Androl2006; 29: 155–165.
20.
RudelRAGrayJMEngelCL, et al.Food packaging and bisphenol A and bis(2-ethyhexyl) phthalate exposure: findings from a dietary intervention. Environ Health Perspect2011; 119: 914–920.
21.
García-FabilaMMChávezAAMezaJCS, et al.Phthalates in the diet of Mexican children of school age risk analysis. Toxicol Rep2020; 7: 1487–1494.
22.
RhodesCElcombeCRBattenPL, et al.The disposition of 14C-di-2-ethylhexylphthalate (DEHP) in the marmoset. Dev Toxicol Environ Sci1983; 11: 579–581.
23.
MettangTPauli-MagnusCAlscherDM, et al.Influence of plasticizer-free CAPD bags and tubings on serum, urine, and dialysate levels of phthalic acid esters in CAPD patients. Perit Dial Int2000; 20: 80–84.
24.
NässbergerLArbinAOsteliusJ. Exposure of patients to phthalates from polyvinyl chloride tubes and bags during dialysis. Nephron1987; 45: 286–290.
25.
WanXWangWLiuJ, et al.Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Method2014; 14: 135.
26.
ZhouJ-HNiZ-HMeiC-L, et al.Efficacy and safety of Changfu peritoneal dialysis solution: a multi-center prospective randomized controlled trial. Chin Med J (Engl)2013; 126: 4204–4209.
27.
ZhouJCaoXLinH, et al.Safety and effectiveness evaluation of a domestic peritoneal dialysis fluid packed in non-PVC bags: study protocol for a randomized controlled trial. Trials2015; 16: 592–592.
28.
Huaren Pharmaceutical: announcement on the interim report of the company’s peritoneal dialysate comparison test results (2016). Huaren Pharmaceutical Announcement Number: 2016-079.
29.
FracassoACaloLLandiniS, et al.Peritoneal sclerosis: role of plasticizers in stimulating interleukin-1 production. Perit Dial Int1993; 13(Suppl 2): S517–519.
30.
StabelliniGBedaniPLFiocchiO, et al.DEHP-induced alterations in the lining tissue of the rat air pouch. Int J Artif Organs1998; 21: 87–94.
31.
ManeraKEJohnsonDWCraigJC, et al.Establishing a core outcome set for peritoneal dialysis: report of the SONG-PD (standardized outcomes in nephrology-peritoneal dialysis) consensus workshop. Am J Kidney Dis2020; 75: 404–412.
32.
ManeraKETongACraigJC, et al.An international Delphi survey helped develop consensus-based core outcome domains for trials in peritoneal dialysis. Kidney Int2019; 96: 699–710.
33.
SahlawiMAWilsonGStallardB, et al.Peritoneal dialysis-associated peritonitis outcomes reported in trials and observational studies: a systematic review. Perit Dial Int2020; 40: 132–140.
34.
DigenisGEAbrahamGSavinE, et al.Peritonitis-related deaths in continuous ambulatory peritoneal dialysis (CAPD) patients. Perit Dial Int1990; 10: 45–47.
35.
TzamaloukasAHMurataGHFoxL. Peritoneal catheter loss and death in continuous ambulatory peritoneal dialysis peritonitis: correlation with clinical and biochemical parameters. Perit Dial Int1993; 13(Suppl 2): S338–340.
36.
FriedLFBernardiniJJohnstonJR, et al.Peritonitis influences mortality in peritoneal dialysis patients. J Am Soc Nephrol1996; 7: 2176–2182.
37.
BoudvilleNKempAClaytonP, et al.Recent peritonitis associates with mortality among patients treated with peritoneal dialysis. J Am Soc Nephrol2012; 23: 1398–1405.
38.
LambertMCLageCKirchgessnerJ.Stay.Safe. A new PVC free system in long-term CAPD treatment. Edtna Erca J1999; 25: 30–34.
39.
BalteauPRPelusoFPColesGA, et al.Design and testing of the baxter integrated disconnect systems (IDS). Perit Dial Int1991; 11: 131–136.
40.
Van BiesenWKirchgessnerJSchillingH, et al.Stay.Safe®, a new PVC-free system for PD: results of the multicenter trial. Perit Dial Int1999; 19: S43.
41.
MarshallMFoongPPDuddingtonM. SAT-270 peritonitis risk with external clamp versus internal disc connectology for peritoneal dialysis: a scoping review. Kidney Int Rep2020; 5: S114–S115(Abstract).
42.
Baxter Healthcare Inc. NCT03812679: performance evaluation of the AMIA APD solution generation system in patients end stage renal disease (ESRD). Study results. Deerfield: Baxter Healthcare Inc, 2021.
43.
TenckhoffHMestonBShilipetarG. A simplified automatic peritoneal dialysis system. Trans Am Soc Artif Intern Organs1972; 18: 436–440.
44.
TenckhoffHShilipetarGVan PaasschenWH, et al.A home peritoneal dialysate delivery system. Trans Am Soc Artif Intern Organs1969; 15: 103–107.
45.
KaranicolasSOreopoulosDGPylypchukG, et al.Home peritoneal dialysis: 3 years’ experience in Toronto. Can Med Assoc J1977; 116: 266–269.
46.
van GelderMKJongJAWFolkertsmaL, et al.Urea removal strategies for dialysate regeneration in a wearable artificial kidney. Biomaterials2020; 234: 119735.
47.
FooMWYHtayH. Innovations in peritoneal dialysis. Nat Rev Nephrol2020; 16: 548–549.
RoncoCFecondiniL. The Vicenza wearable artificial kidney for peritoneal dialysis (ViWAK PD). Blood Purif2007; 25: 383–388.
50.
BuoncristianiUBianchiPCozzariM, et al.A new safe simple connection system for CAPD. Int J Nephrol Urol Androl1980; 1: 50–53.
51.
BuoncristianiU. Birth and evolution of the “Y” set. ASAIO J1996; 42: 8–11.
52.
BuoncristianiUQuintalianiGCozzariM, et al.Current status of the Y set. Adv Perit Dials Conf Perit Dial1986; 1: 165–171.
53.
MaiorcaRCantaluppiACancariniGC, et al.Prospective controlled trial of a Y-connector and disinfectant to prevent peritonitis in continuous ambulatory peritoneal dialysis. Lancet1983; 2: 642–644.
54.
BuoncristianiUCarobiCCozzariM, et al.Clinical application of a miniaturized variant of the Perugia CAPD connection system. In: MaherJFWinchesterJF (eds) Frontiers in peritoneal dialysis. Berlin, Heidelberg: Springer Berlin Heidelberg, 1986, pp. 193–197.
55.
BazzatoGColiULandiniS, et al.Continuous ambulatory peritoneal dialysis without wearing a bag: complete freedom of patient and significant reduction of peritonitis. Proc Eur Dial Transplant Assoc1980; 17: 266–275.
56.
BazzatoGLandiniSColiU, et al.A new technique of continuous ambulatory peritoneal dialysis (CAPD): double-bag system for freedom to the patient and significant reduction of peritonitis. Clin Nephrol1980; 13: 251–254.
57.
MistryCDGokalR. Alternative osmotic agents. Blood Purif1989; 7: 109–114.
58.
MistryCDGokalR. Glucose polymer as an osmotic agent in CAPD. Adv Exp Med Biol1989; 260: 149–156.
59.
MistryCDGokalRPeersE. A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS study group. Multicenter investigation of icodextrin in ambulatory peritoneal dialysis. Kidney Int1994; 46: 496–503.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
